![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
INTERIM ANALYSIS OF A 3-YEAR FOLLOW-UP STUDY OF NS5A AND NS3 RESISTANCE-ASSOCIATED VARIANTS AFTER TREATMENT WITH GRAZOPREVIR-CONTAINING REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
|
|
|
Reported by Jules Levin
AASLD 2026 Nov 11-15 Boston, MA
Frederick Lahser, Angela Galloway, Peggy Hwang, John Palcza, Janice Wahl, Michael Robertson, Eliav Barr, Todd Black, Ernest Asante-Appiah, Barbara Haber
Merck & Co., Inc. Kenilworth, NJ, USA
![HIV1](../images/111716/111716-14/HIV1.gif)
![HIV2](../images/111716/111716-14/HIV2.gif)
![HIV3](../images/111716/111716-14/HIV3.gif)
![HIV4](../images/111716/111716-14/HIV4.gif)
![HIV5](../images/111716/111716-14/HIV5.gif)
![HIV6](../images/111716/111716-14/HIV6.gif)
![HIV7](../images/111716/111716-14/HIV7.gif)
![HIV8](../images/111716/111716-14/HIV8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|